Marlon C. Rebelatto

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma et al. · Journal of Clinical Oncology · 2016 · 845 citations · Full text

Medicine, Oncology, Urology +17

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

John Y. Li, Samuel R. Perry, Vanessa Muniz‐Medina et al. · Cancer Cell · 2016 · 390 citations · Full text

Medicine, Oncology, Pharmacology +14

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer

M. Ratcliffe, Alan Sharpe, Anita Midha et al. · Clinical Cancer Research · 2017 · 304 citations

Medicine, Oncology, Cancer Immunology +16

The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

Janis M. Taube, Güray Aktürk, Michael Angelo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 288 citations · Full text

Medicine, Oncology, Pathology +17

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

Luana Calabrò, Aldo Morra, Diana Giannarelli et al. · The Lancet Respiratory Medicine · 2018 · 216 citations

Pharmacy, Oncology, Pharmacotherapy +9